Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex

Journal of Clinical Investigation

Volumn 114, Issue 8, 2004, Pages 1058-1071

  Li, Hui Hua ^a   Kedar, Vishram ^a   Zhang, Chunlian ^a   McDonough, Holly ^a   Arya, Ranjana ^a   Wang, Da Zhi ^a   Patterson, Cam ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTININ 2; CALCINEURIN; CALCINEURIN A; F BOX PROTEIN; MUSCLE PROTEIN; PROTEIN; PROTEIN CUL1; PROTEIN ROC1; S PHASE KINASE ASSOCIATED PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC4; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ADENOVIRUS; AGONIST; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; HEART; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; INHIBITION KINETICS; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; STIMULATION; THORACIC AORTA; TRANSGENIC MOUSE; UBIQUITINATION;

ACTININ; ANIMALS; CALCINEURIN; CARDIOMEGALY; CELL CYCLE PROTEINS; CERCOPITHECUS AETHIOPS; COS CELLS; CULLIN PROTEINS; ECHOCARDIOGRAPHY; F-BOX PROTEINS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; MACROMOLECULAR SUBSTANCES; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; ORGAN SIZE; RATS; RECOMBINANT FUSION PROTEINS; SKP CULLIN F-BOX PROTEIN LIGASES; TRANSCRIPTION, GENETIC; TWO-HYBRID SYSTEM TECHNIQUES; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 9644270401     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200422220     Document Type: Article

References (54)

1. Molkentin, J.D. 2000. Calcineurin and beyond: cardiac hypertrophic signaling. Circ. Res. 87:731-738.
2. Vakili, B.A., Okin, P.M., and Devereux, R.B. 2001. Prognostic implications of left ventricular hypertrophy. Am. Heart J. 141:334-341.
3. Chien, K.R. 1999. Stress pathways and heart failure. Cell. 98:555-558.
4. Molkentin, J.D., et al. 1998. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:215-228.
5. Frey, N., Richardson, J.A., and Olson, E.N. 2000. Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc. Natl. Acad. Sci. U. S. A. 97:14632-14637.
6. Bueno, O.F., et al. 2002. Impaired cardiac hypertrophic response in Calcineurin Abeta-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 99:4586-4591.
7. De Windt, L.J., et al. 2001. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:3322-3327.
8. Taigen, T., De Windt, L.J., Lim, H.W., and Molkentin, J.D. 2000. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 97:1196-1201.
9. Coghlan, V.M., et al. 1995. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. Science. 267:108-111.
10. Vega, R.B., Yang, J., Rothermel, B.A., Bassel-Duby, R., and Williams, R.S. 2002. Multiple domains of MCIP1 contribute to inhibition of calcineurin activity. J. Biol. Chem. 277:30401-30407.
11. Bodine, S.C., et al. 2001. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294:1704-1708.
12. Gomes, M.D., Lecker, S.H., Jagoe, R.T., Navon, A., and Goldberg, A.L. 2001. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. U. S. A. 98:14440-14445.
13. Jackson, P.K., et al. 2000. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol. 10:429-439.
14. Jackson, P.K., and Eldridge, A.G. 2002. The SCF ubiquitin ligase: an extended look. Mol. Cell. 9:923-925.
15. Delling, U., et al. 2000. A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression. Mol. Cell. Biol. 20:6600-6611.
16. van Rooij, E., et al. 2002. Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy. J. Biol. Chem. 277:48617-48626.
17. Deshaies, R.J. 1999. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu. Rev. Cell Dev. Biol. 15:435-467.
18. Jiang, J., et al. 2001. CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J. Biol. Chem. 276:42938-42944.
19. Lindsten, K., Menendez-Benito, V., Masucci, M.G., and Dantuma, N.P. 2003. A transgenic mouse model of the ubiquitin/proteasome system. Nat. Biotechnol. 21:897-902.
20. Subramaniam, A., et al. 1991. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J. Biol. Chem. 266:24613-24620.
21. van Rooij, E., et al. 2004. MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ. Res. 94:e18-e26.
22. Vega, R.B., Bassel-Duby, R., and Olson, E.N. 2003. Control of cardiac growth and function by calcineurin signaling. J. Biol. Chem. 278:36981-36984.
23. Wilkins, B.J., et al. 2004. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 94:110-118.
24. Esposito, G., et al. 2002. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 105:85-92.
25. Hill, J.A., et al. 2002. Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. J. Biol. Chem. 277:10251-10255.
26. Youn, H.D., Sun, L., Prywes, R., and Liu, J.O. 1999. Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2. Science. 286:790-793.
27. Bush, E., et al. 2004. A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 101:2870-2875.
28. Hashimoto, Y., and Soderling, T.R. 1989. Regulation of calcineurin by phosphorylation. Identification of the regulatory site phosphorylated by Ca2+/calmodulin-dependent protein kinase II and protein kinase C. J. Biol. Chem. 264:16524-16529.
29. Knoll, R., et al. 2002. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell. 111:943-955.
30. Mukai, H., et al. 1997. Interaction of PKN with alpha-actinin. J. Biol. Chem. 272:4740-4746.
31. Freeman, J.L., Pitcher, J.A., Li, X., Bennett, V., and Lefkowitz, R.J. 2000. α-Actinin is a potent regulator of G protein-coupled receptor kinase activity and substrate specificity in vitro. FEBS Lett. 473:280-284.
32. Park, J.P., et al. 2000. Amplification of the MLL region in acute myeloid leukemia. Cancer Genet. Cytogenet. 121:198-205.
33. Zheng, N., et al. 2002. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature. 416:703-709.
34. Bai, C., et al. 1996. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell. 86:263-274.
35. Skowyra, D., Craig, K.L., Tyers, M., Elledge, S.J., and Harper J.W. 1997. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell. 91:209-219.
36. Feldman, R.M., Correll, C.C., Kaplan, K.B., and Deshaies, R.J. 1997. A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell. 91:221-230.
37. Lim, H.W., et al. 2000. Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. Circulation. 101:2431-2437.
38. Stitt, T.N., et al. 2004. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell. 14:395-403.
39. Sandri, M., et al. 2004. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117:399-412.
40. Frey, N., Katus, H.A., Olson, E.N., and Hill, J.A. 2004. Hypertrophy of the heart: a new therapeutic target? Circulation. 109:1580-1589.
41. Yang, G., et al. 2001. Cyclosporine reduces left ventricular mass with chronic aortic banding in mice, which could be due to apoptosis and fibrosis. J. Mol. Cell. Cardiol. 33:1505-1514.
42. Pu, W.T., Ma, Q., and Izumo, S. 2003. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ. Res. 92:725-731.
43. Koepp, D., Harper, J., and Elledge, S. 1999. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell. 97:431-434.
44. Levy, D., Garrison, R.J., Savage, D.D., Kannel, W.B., and Castelli, W.P. 1990. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322:1561-1566.
45. Verdecchia, P., et al. 1998. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 97:48-54.
46. Burke, E., and Barik, S. 2003. Megaprimer PCR: application in mutagenesis and gene fusion. Methods Mol. Biol. 226:525-532.
47. Chin, E.R., et al. 1998. A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev. 12:2499-2509.
48. Clipstone, N.A., and Crabtree, G.R. 1992. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 357:695-697.
49. Rothermel, B., et al. 2000. A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. J. Biol. Chem. 275:8719-8725.
50. Dai, Q., et al. 2003. CHIP activates HSF1 and confers protection against apoptosis and cellular stress. EMBO J. 22:5446-5458.
51. Ballinger, C.A., et al. 1999. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell. Biol. 19:4535-4545.
52. Ohta, T., and Xiong, Y. 2001. Phosphorylation-and Skp1-independent in vitro ubiquitination of E2F1 by multiple ROC-cullin ligases. Cancer Res. 61:1347-1353.
53. Jones, W.K., et al. 1996. Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart. J. Clin. Invest. 98:1906-1917.
54. Hill, J.A., et al. 2000. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation. 101:2863-2869.